VSTM · Verastem, Inc.
$6.23
+0.15 (+2.47%)
At close · Jul 28
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In accordance with the applicable accounting standards, these conditions raise substantial doubt about the Company's ability to continue as a going concern for twelve months after the date the condensed consolidated financial statements are issued.”View the 10-Q filed May 7, 2026
Market Cap
$547.45M
Shares
87.87M
Verastem, Inc. Earnings Call Transcripts
Every quarterly earnings call for Verastem, Inc. (VSTM) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
Earnings call
FY26 · Q2
2026-08-06
Verastem Oncology 2Q26 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-23
Verastem Oncology VS-7375 TARGET-D Conference Call
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Verastem, Inc. Q1 FY2026 Earnings Call
Positive tone
VS-7375 KRAS G12D pipeline
Registration-directed Phase II trials
AVMAPKI FAKZYNJA CO-PACK launch performance
Revenue
$18.67M
Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Verastem, Inc. Q4 FY2025 Earnings Call
Positive tone
Pancreatic Cancer (RAMP 205)
VS-7375 KRAS G12D Program
LGSOC Commercial Launch
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Verastem, Inc. Q3 FY2025 Earnings Call
Confident tone
VS-7375 KRAS G12D on/off inhibitor program
Commercial launch execution and physician engagement
Reimbursement and patient access
Revenue
$11.24M
▲ 12.4% YoY Diluted EPS
$-1.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Verastem, Inc. Q2 FY2025 Earnings Call
Confident tone
AVMAPKI FAKZYNJA CO-PACK launch
Commercial execution and sales force
KRAS-mutated recurrent LGSOC
Revenue
$2.14M
Diluted EPS
$-0.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Verastem, Inc. Q4 FY2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q1
2020-04-27
Verastem, Inc. Q1 FY2020 Earnings Call
Revenue
$5.06M
▲ 202.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-28
Verastem, Inc. Q4 FY2019 Earnings Call
Revenue
$3.62M
▲ 198.9% YoY Diluted EPS
$-6.12
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Showing 1–10 of 10 earnings calls
Key facts
CIK
1526119
CUSIP
92337C203
13F (30d)
20 filings
20 filers
Visit website
Investor relations